Dr. Vanessa Roxanne Holland, MD

Dr. Holland practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Holland's NPI, 1659550861, was assigned on October 24, 2007. Dr. Holland graduated from Keck School of Medicine of USC in 2006. Dr. Holland's California license number on file is A101766.

Dr. Holland's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Holland's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Holland is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Holland to 2 more group practices and clinics, 2 medical groups and 1 community health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holland practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Holland's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Holland is board certified in dermatology by the American Board of Dermatology. Dr. Holland has a license on file in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, contact dermatitis, itchy rashes, minor injury to a limb, psoriasis and rash among the conditions Dr. Holland treats.

CMS data shows 755 Medicare services from Dr. Holland across 9 procedure codes in 2024, for 329 Medicare patients. Medicare paid $48,419 for them.

CMS counts 329 Medicare patients who saw Dr. Holland in 2024. The largest group is 65 to 74, with 142 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Holland's median patient age at 56, with 59% women.

In 2024, Dr. Holland wrote 976 Medicare Part D claims for 230 patients. 85% of them were for generic drugs. CMS names the drug for 816 of them, across 23 drugs with 11 or more claims each, at $603,086 in total drug cost. In 2023, CMS named 848 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Holland for performance year 2024, reported as part of a group. Dr. Holland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Holland as offering telehealth. CMS counts 351 procedures of removal of skin lesions by Dr. Holland, more than 83% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Holland, published from 2017 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Diagnosis, Differential. Dr. Holland has published most often in JAAD Case Rep. Dr. Holland's most frequent co-authors are Julia S. Arzeno, MD, Elaine Dong and Carolyn Goh, MD.

CMS Open Payments shows 16 general payments to Dr. Holland from 11 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $125.

Dmand AI lists 2 awards for Dr. Holland, most recently CMS Stage 1 EHR in 2013.

Dr. Holland graduated from Keck School of Medicine of USC in 2006. Dr. Holland is a member of AAD.

Dr. Holland is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.